Clinical characteristics and outcomes of adults with Philadelphia chromosome positive and/or bcr-abl positive acute lymphoblastic leukemia: a single center study from China

Autor:	Yingchang Mi, Yenan Li, Yaozhong Zhao, Lugui Qiu, Jianxiang Wang, Dehui Zou
Rok vydání:	2010
Předmět:	Adult Male Cancer Research medicine.medical_specialty Adolescent medicine.medical_treatment Fusion Proteins bcr-abl Antineoplastic Agents Single Center Philadelphia chromosome Gastroenterology Disease-Free Survival Piperazines hemic and lymphatic diseases Internal medicine medicine Humans Transplantation Homologous Retrospective Studies Chemotherapy Philadelphia Chromosome Positive business.industry Imatinib Retrospective cohort study Hematology Middle Aged Precursor Cell Lymphoblastic Leukemia-Lymphoma medicine.disease Transplantation Imatinib mesylate Pyrimidines Treatment Outcome Oncology Immunology Benzamides Imatinib Mesylate Female business medicine.drug Stem Cell Transplantation
Zdroj:	Leukemialymphoma. 51(3)
ISSN:	1029-2403
Popis:	The study reviewed 389 adult patients with acute lymphoblastic leukemia (ALL) and 110 patients (28.3%) were diagnosed as Philadelphia chromosome positive (Ph-positive) and/or bcr-abl positive ALL. The special group had the same clinical characteristics as other studies, except for relatively young age and high incidence of both P190 and P210 fusion proteins expression. The complete remission (CR) rate in conventional chemotherapy (CT) group and in chemotherapy combined with imatinib (ICT) group was 84.7% and 96.0%, respectively. The 2-year disease-free survival (DFS) and overall survival (OS) were 0 and 23.6 +/- 6.9%, respectively in CT group; the 2-year DFS and OS were 22.1 +/- 8.8% and 41.6 +/- 10.0%, respectively in ICT group; and in allogeneic stem cell transplantation (SCT) group, the 2-year DFS and OS were 48.2 +/- 13.9% and 53.1 +/- 12.7%, respectively. The results of the study indicated that introducing imatinib into treatment of patients with Ph-positive ALL could improve CR rate and survival, especially as early as possible, and allogenic SCT was still the first choice for these patients if they had suitable donors.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ce31f6bcd7bed4b04f7df32115072c9 https://pubmed.ncbi.nlm.nih.gov/20141436 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.